



STATE OF WEST VIRGINIA  
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Bill J. Crouch  
Cabinet Secretary

Bureau for Medical Services  
Pharmacy Services  
350 Capitol Street – Room 251  
Charleston, West Virginia 25301-3706  
Telephone: (304) 558-1700 Fax: (304) 558-1542

Cynthia E. Beane  
Commissioner

*Pharmaceutical and Therapeutics  
Committee*  
April 25th, 2018

Location: Diamond, Rooms B10 and B11  
Time: 2:00 PM – 5:00 PM  
Charleston, WV 25301  
(304) 558-1700

## MINUTES

**Committee Members Present:**

Tom Kines, R.Ph., Vice-Chair  
Chris Terpening, Pharm.D., PhD.  
Toni DiChiacchio, DNP  
Philip Galapon, M.D. FAAFP  
Kelli Lynn Jennings, Pharm.D.  
Karrie Juengel, Pharm.D.  
Heather Jones, PA-C  
Charles Rohrbaugh, R.Ph.  
James Rising, M.D.

By Phone:

Absent:  
Bradley Henry, M.D., Chair  
Hani Nazha, M.D.  
John Bernabei, R.Ph.  
Mitzi Payne, M.D.  
Steve Neal, Pharm.D

**Division of Medicaid Staff Present:**

Vicki Cunningham, R.Ph.  
Brian Thompson, Pharm.D., MS  
Bill Hopkins  
Doug Sorvig  
Gail Goodnight  
Fred Lewis, Deputy Commissioner

**Contract Staff/CHC Staff Present:**

Brent Breeding, R.Ph  
Jeff Barkin, M.D.  
Jennifer Seymour, Operational Account  
Coordinator (by phone)

**Other Contract / State Staff Present:**

## **I. Call to Order Minutes**

Tom Kines, Vice-chairman, called the meeting to order at 2:06pm

## **II. Welcome and Introductions**

P&T committee members introduced themselves.

## **III. Administrative Items / Updates**

Vicki Cunningham provided ground rules for public comments and directions for evacuation in the event of an emergency.

### **A. Approval of the January 24th, 2018 Minutes**

Chris Terpening made a motion to approve the minutes from the meeting held on October 25, 2017. The motion was seconded by Philip Galapon. All were in favor and the minutes were approved.

### **B. PDL Compliance/Generic Percent Report Updates**

Dr. Barkin provided an explanation of the PDL Compliance and Generic Percent reports.

**A.** Dr. Barkin reviewed the Generic Percent Report; overall generic utilization for Q1 2018 was 86.5%

**B.** Dr. Barkin reviewed the PDL Compliance Report; overall compliance for Q1 2018 was 91%.

## **IV. Public Comments**

Will Hancock, representing NovoNordisk, spoke in favor of Fiasp.

## **V. Executive Session**

A motion was made to move to executive session by Chris Terpening and seconded by Charlie Rohrbaugh and all were in favor.

The Committee adjourned for executive session at 2:19pm.

The Committee reconvened at 3:13pm.

## **VI. New Business**

### **A. Adjustments to Existing Classes**

#### **i. MITGARE & colchicine capsules**

## ANTIHYPERURICEMICS

ANTIHYPERURICEMICS	
ANTIMITOTICS	
MITIGARE (colchicine)*	colchicine capsules* colchicine tablets COLCRYS (colchicine)

Charles Rohrbaugh made a motion to approve the changes to the Antihyperuricemics category as recommended; the motion was seconded by Philip Galapon. All members were in favor and the motion was approved.

### ii. EFFIENT

## PLATELET AGGREGATION INHIBITORS

AGGRENOX (dipyridamole/ASA) BRILINTA (ticagrelor) clopidogrel prasugrel	clopidogrel kit dipyridamole dipyridamole/aspirin DURLAZA ER (aspirin) EFFIENT (prasugrel) PERSANTINE (dipyridamole) PLAVIX (clopidogrel) TICLID (ticlopidine) ticlopidine ZONTIVITY (vorapaxar)
--	---

Chris Terpening and made a motion to approve the changes to the Platelet Aggregation Inhibitors category as recommended; the motion was seconded by Charles Rohrbaugh. All members were in favor and the motion was approved.

### iii. CONCERTA & methylphenidate ER

## STIMULANTS AND RELATED AGENTS

NON-AMPHETAMINE	
APTENSIO XR (methylphenidate) armodafinil <sup>CL</sup> atomoxetine clonidine IR COTEMPLA XR ODT (methylphenidate)** DAYTRANA (methylphenidate) dexamethylphenidate IR FOCALIN XR (dexamethylphenidate) guanfacine ER guanfacine IR METADATE CD (methylphenidate) discontinued by labeler METHYLIN SOLUTION (methylphenidate) methylphenidate IR modafinil <sup>CL</sup> QUILLICHEW ER (methylphenidate)	clonidine ER* CONCERTA (methylphenidate) dexamethylphenidate XR FOCALIN IR (dexamethylphenidate) INTUNIV (guanfacine extended-release) KAPVAY (clonidine extended-release)* methylphenidate CD methylphenidate chewable tablets, solution methylphenidate ER methylphenidate ER (generic CONCERTA) methylphenidate LA NUVIGIL (armodafinil) PROVIGIL (modafinil) QUILLIVANT XR (methylphenidate) RITALIN (methylphenidate) RITALIN LA (methylphenidate) STRATTERA (atomoxetine)***

Chris Terpening made a motion to approve the changes to the Stimulants and Related Agents category as recommended; the motion was seconded by Philip Galapon. All members were in favor and the motion was approved. The P&T Committee recommended that grandfathering of the current preferred agents that will become non-preferred only be approved through the current school year. This will be addressed at the next Drug Utilization Review Board meeting.

## B. New Therapeutic Class

### i. ROSACEA AGENTS

#### ACNE AGENTS, TOPICAL

FINACEA GEL (azelaic acid) MIRVASO GEL (brimonidine) metronidazole cream metronidazole gel (NDCs 00115-1474-46, 00168-0275-45, 00713-0637-37, 51672-4116-06, 66993-0962-45 only)	FINACEA FOAM (azelaic acid) METROCREAM (metronidazole) METROGEL GEL (metronidazole) METROLOTION (metronidazole) metronidazole lotion metronidazole gel (all other NDCs) NORITATE CREAM (metronidazole) RHOFADÉ (oxymetazoline) ROSADAN (metronidazole) SOOLANTRA CREAM (metronidazole)	
---	---	--

James Rising made a motion to approve the addition of a Rosacea Agents sub-class as recommended to the Acne Agents, Topical therapeutic class; the motion was seconded by Charles Rohrbaugh. All members were in favor and the motion was approved.

## C. New Generics

### i. Paroxetine 7.5 mg capsules

#### ANTIDEPRESSANTS, SSRIs

citalopram escitalopram tablets fluoxetine capsules, solution fluvoxamine paroxetine sertraline	BRISDELLE (paroxetine) CELEXA (citalopram) escitalopram solution fluoxetine tablets fluvoxamine ER LEXAPRO (escitalopram) LUVOX CR (fluvoxamine) paroxetine 7.5 mg capsules paroxetine ER PAXIL (paroxetine) PAXIL CR (paroxetine) PEXEVA (paroxetine) PROZAC (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline)	
--	---	--

Chris Terpening made a motion to approve the changes to the Antidepressants, SSRIs category as recommended; the motion was seconded by Charles Rohrbaugh. All members were in favor and the motion was approved.

**ii. Fosamprenavir**

ANTIRETROVIRALS		
PROTEASE INHIBITORS (PEPTIDIC)		
EVOTAZ (atazanavir/cobicistat)	CRIXIVAN (indinavir)	
NORVIR (ritonavir)	INVIRASE (saquinavir mesylate)	
REYATAZ (atazanavir)	<b>fosamprenavir</b>	
	LEXIVA (fosamprenavir)	
	VIRACEPT (nelfinavir mesylate)	

Chris Terpening made a motion to approve the changes to the Antiretrovirals, Protease Inhibitors(Peptidic) category as recommended; the motion was seconded by Charles Rohrbaugh. All members were in favor and the motion was approved.

**iii. Prasugrel**

PLATELET AGGREGATION INHIBITORS		
AGGRENOX (dipyridamole/ASA)	clopidogrel kit	
BRILINTA (ticagrelor)	dipyridamole	
clopidogrel	dipyridamole/aspirin	
<b>prasugrel</b>	DURLAZA ER (aspirin)	
	EFFIENT (prasugrel)	
	PERSANTINE (dipyridamole)	
	PLAVIX (clopidogrel)	
	TICLID (ticlopidine)	
	ticlopidine	
	ZONTIVITY (vorapaxar)	

Chris Terpening made a motion to approve the changes to Platelet Aggregation Inhibitors category as recommended; the motion was seconded by Charles Rohrbaugh. All members were in favor and the motion was approved.

**D. New Drug Reviews**

**i. DUZALLO**

ANTIHYPERURICEMICS		
URICOSURIC – XANTHINE OXIDASE INHIBITORS		
	<b>DUZALLO (allopurinol/lesinurad)</b>	

Charles Rohrbaugh made a motion to approve the changes to the Antihyperuricemics category as recommended; the motion was seconded by Chris Terpening. All members were in favor and the motion was approved.

**ii. BIKTARVY**

<b>ANTIRETROVIRALS</b>		
<b>COMBINATION PRODUCTS – INTEGRASE STRAND TRANSFER INHIBITORS &amp; NUCLEOSIDE ANALOG RTIs</b>		
<b>BIKTARVY</b> (bictegravir/emtricitabine/tenofovir alafenamide)		

Chris Terpening made a motion to approve the changes to the Antiretrovirals Agents category as recommended; the motion was seconded by Karrie Juengel. All members were in favor and the motion was approved.

**iii. TRELEGY ELLIPTA**

<b>COPD AGENTS</b>		
<b>ANTICHOLINERGIC-BETA AGONIST-GLUCOCORTICOID COMBINATIONS</b>		
	<b>Trelegy Ellipta</b> (fluticasone/umeclidinium/vilanterol)	

Chris Terpening made a motion to approve the changes to the COPD Agents category as recommended; the motion was seconded by Philip Galapon. All members were in favor and the motion was approved.

**iv. BAXDELA**

<b>FLUOROQUINOLONES (Oral)</b>		
CIPRO SUSPENSION (ciprofloxacin) ciprofloxacin levofloxacin tablet	AVELOX (moxifloxacin) <b>BAXDELA</b> (delafloxacin) CIPRO TABLETS (ciprofloxacin) CIPRO XR (ciprofloxacin) ciprofloxacin ER ciprofloxacin suspension FACTIVE (gemifloxacin) LEVAQUIN (levofloxacin) levofloxacin solution moxifloxacin NOROXIN (norfloxacin) ofloxacin	

Charles Rohrbaugh made a motion to approve the changes to the Fluoroquinolones, Oral Agents category as recommended; the motion was seconded by Chris Terpening. All members were in favor and the motion was approved.

**v. ARMONAIR RESPICLICK & QVAR REDIHALER**

<b>GLUCOCORTICIDS, INHALED</b>		
<b>GLUCOCORTICIDS</b>		
FLOVENT Diskus (fluticasone) FLOVENT HFA (fluticasone) PULMICORT FLEXHALER (budesonide)	AEROSPAN (flunisolide)** ALVESCO (ciclesonide) <b>ARMONAIR RESPICLICK</b> (fluticasone) ARNUITY ELLIPTA (fluticasone) ASMANEX HFA (mometasone)	

PULMICORT RESPULES (budesonide)* QVAR (beclomethasone) QVAR REDHALER (beclomethasone)	ASMANEX TWISTHALER (mometasone) budesonide	
---	---	--

Charles Rohrbaugh made a motion to approve the changes to the Glucocorticoids, Inhaled Agents category as recommended with the stipulation that QVAR Redihaler be preferred pending financials confirmation; the motion was seconded by Philip Galapon and Chris Terpening. All members were in favor and the motion was approved.

**vi. FIASP**

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS		
HUMALOG (insulin lispro) HUMALOG MIX VIALS (insulin lispro/lispro protamine) HUMULIN VIALS (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine)	AFREZZA (insulin) APIDRA (insulin glulisine) BASAGLAR (insulin glargine) FIASP (insulin aspart) HUMALOG JR KWIKPEN (insulin lispro) HUMALOG PEN/KWIKPEN (insulin lispro) HUMALOG MIX PENS (insulin lispro/lispro protamine) HUMULIN PENS (insulin) NOVOLIN (insulin) SOLIQUA (insulin glargine/lixisenatide) TOUJEO SOLOSTAR (insulin glargine) TRESIBA (insulin degludec) XULTOPHY (insulin degludec/liraglutide)	

Chris Terpening made a motion to approve the changes to the Hypoglycemics, Insulin and Related Agents category as recommended; the motion was seconded by Philip Galapon. All members were in favor and the motion was approved.

**vii. SYMPROIC**

IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROME/SELECTED GI AGENTS		
AMITIZA (lubiprostone) MOVANTIK (naloxegol)	LINZESS (linaclotide) RELISTOR INJECTION (methylnaltrexone) RELISTOR TABLET (methylnaltrexone) SYMPROIC (naldemedine) TRULANCE (plecanatide)	

Charles Rohrbaugh made a motion to approve the changes to the IBS/SBS/Selected GI Agents category as recommended; the motion was seconded by James Rising. All members were in favor and the motion was approved.

**viii. COTEMPLA XR ODT**

STIMULANTS AND RELATED AGENTS		
NON-AMPHETAMINE		
APTENSIO XR (methylphenidate) armodafinil <sup>CL</sup> atomoxetine clonidine IR COTEMPLA XR ODT (methylphenidate)** DAYTRANA (methylphenidate)	clonidine ER* CONCERTA (methylphenidate) dexmethylphenidate XR FOCALIN IR (dexmethylphenidate) INTUNIV (guanfacine extended-release) KAPVAY (clonidine extended-release)* methylphenidate CD	

dexamethylphenidate IR FOCALIN XR (dexamethylphenidate) guanfacine ER guanfacine IR METADATE CD (methylphenidate) discontinued by labeler METHYLIN SOLUTION (methylphenidate) methylphenidate IR modafinil <sup>CL</sup> QUILLICHEW ER (methylphenidate)	methylphenidate chewable tablets, solution methylphenidate ER methylphenidate ER (generic CONCERTA) methylphenidate LA NUVIGIL (armodafinil) PROVIGIL (modafinil) QUILLIVANT XR (methylphenidate) RITALIN (methylphenidate) RITALIN LA (methylphenidate) STRATTERA (atomoxetine)	
---	---	--

Chris Terpening made a motion to approve the changes to the Stimulants and Related Agents category as recommended; the motion was seconded by Philip Galapon.. All members were in favor and the motion was approved.

## VII. Old Business

There was no old business to be discussed at this time.

## VIII. Other Business

## IX. Next Meeting

The next meeting will be held on August 22<sup>nd</sup>, 2018 2pm-5pm in Diamond Rooms B10 and B11.

## X. Adjournment

Dr. Kines adjourned the meeting at 3:42pm.